Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Duodenal Mucosa Responses to Endoscopic Food Challenges in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome With Self-reported Food Intolerances: A Feasibility Study (DRFC)

12 de noviembre de 2026 actualizado por: David Armstrong, McMaster University

Duodenal Responses to Food Challenges in Patients With Self-reported Food Intolerances: a Feasibility Study

The goal of this study is to investigate the feasibility of using intravenous fluorescein during a standard endoscopy-along with a laser to activate it and an optical filter-to identify changes in the duodenal mucosa after a controlled food challenge in individuals with IBD and IBS who experience food intolerances. The main questions it aims to answer are:

  • Is this technique feasible approach to assess food intolerances in patients with IBD and IBS?
  • Does patients with IBD and IBS exhibit acute tissue changes upon exposure to specific food antigens?

Researches will compare the food antigen to a placebo solution (saline solution without an antigen) to see if the reaction in the tissue is different.

Participants will:

  • Answer questionnaires.
  • Provide a blood and stool sample.
  • Take an allergy test.
  • Undergo an upper endoscopy.

Descripción general del estudio

Descripción detallada

This is a prospective, double-arm, randomized feasibility study. This study will recruit patients with Inflammatory Bowel Disease (IBD) in remission and patients with Irritable Bowel Syndrome (IBS), who self-report food intolerances. All participants will undergo an upper endoscopy with the administration of a food challenge solution (cow's milk protein or placebo), intravenous fluoresceine administration, biopsies and fluid collection.

Upon signing informed consent, participants will be enrolled in the study. Following enrollment, participants will be randomized in a 2:1 ratio to receive either a food challenge with a cow's milk protein solution or a placebo solution during the upper endoscopy, which will occur in visit 3.

During the first visit, participants will complete questionnaires covering demographics, medical history, gastrointestinal symptoms (using the Gastrointestinal Symptoms Rating Scale), and food intolerances. Blood samples will be collected from all participants, and IBD patients will additionally provide stool samples for fecal calprotectin measurement.

In the second visit, participants will be evaluated by an experienced allergologist, and a skin prick test will be conducted to rule out an allergy to cow's milk protein.

After completing these initial evaluations, participants will be scheduled for visit 3. In preparation for this visit, participants will be instructed to avoid consuming any products containing cow's milk for five days prior. During visit 3, an upper endoscopy will be performed. Through the endoscope's working channel, either a cow's milk protein solution or a placebo solution will be delivered to the third portion of the duodenum. Additionally, eight biopsies and a fluid sample will be collected from this area. A permeability test will also be performed using intravenous fluorescein, and the procedure will be recorded on video.

Following the third visit, a follow-up phone call will be conducted to assess any symptoms that participants may have experienced post-procedure.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

12

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: David Armstrong, MD
  • Número de teléfono: 76404 905 521 2100
  • Correo electrónico: armstro@mcmaster.ca

Copia de seguridad de contactos de estudio

  • Nombre: Liam Rondeau, PhD
  • Número de teléfono: 76404 19055259140
  • Correo electrónico: rondeaul@mcmaster.ca

Ubicaciones de estudio

    • Ontario
      • Hamilton, Ontario, Canadá, L8S 4K1
        • McMaster University Medical Centre
        • Investigador principal:
          • David Armstrong, MD
        • Contacto:
          • David Armstrong, MD
          • Número de teléfono: 76404 905 521 2100
          • Correo electrónico: armstro@mcmaster.ca

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Confirmed diagnosis of IBD (UC or CD) and under clinical remission for at least 3 months, OR confirmed diagnosis of IBS (any subtype) by Rome IV criteria.
  • Report having one or more food intolerance.
  • Able to provide informed consent.

Exclusion Criteria:

  • Presence of a known food allergy.
  • Presence of serum IgE positivity or a positive skin-prick test to cow's milk.
  • Known allergy to fluorescein.
  • Diagnosis of celiac disease.
  • Positive IgA TTG antibodies.
  • Pregnancy or breastfeeding.
  • Presence of a contraindication for an upper endoscopy.
  • History of surgery involving the upper gastrointestinal tract.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Cow's milk protein solution

A solution with 5 mL cow's milk protein fraction mixed with 50% sterile water applied onto the duodenal mucosa one time during an upper endoscopy.

Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis

Otros nombres:
  • EGD
  • esofagogastroduodenoscopia
Comparador de placebos: Placebo solution

A solution with 18 mL sterile water + 2 mL simethicone applied onto the duodenal mucosa one time during an upper endoscopy.

Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis

Otros nombres:
  • EGD
  • esofagogastroduodenoscopia

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Procedure completition
Periodo de tiempo: From the start of the endoscopy up to 10 minutes after the food challenge

Successful completion of the procedure including sample collection, administration of the food challenge, and development of a reaction in the duodenal mucosa. A positive reaction in the mucosa will be defined by the presence of intraepithelial lymphocytes >25/100 epithelial cells.

From the start of the endoscopy up to 10 minutes after the food challenge

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de febrero de 2027

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de marzo de 2028

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir